Enodia Therapeutics has acquired preclinical assets from Kezar Life Sciences' (NASDAQ: KZR) Sec61-based discovery and development program under a deal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE